About bevacizumab
Vascular endothelial growth factor inhibitor
Used for
- Certain cancers, including colorectal, lung, kidney, ovarian, cervical, and brain cancers
Usual adult dose
Usually 5–15 mg/kg by intravenous infusion every 2–3 weeks, depending on cancer and treatment regimen.
Common side effects
- High blood pressure
- Bleeding or blood clots
- Protein in urine
- Delayed wound healing
Important warnings
- Can cause severe bleeding, bowel perforation, or blood clots.
- May impair wound healing; treatment is usually held around major surgery.
- Monitor blood pressure and urine protein during treatment.
- Use only under specialist supervision; dose depends on cancer and regimen.
Pregnancy
May harm an unborn baby. Avoid during pregnancy and for at least 6 months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment or for 6 months after the last dose.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.